麻豆破解版

 
 
 

Developing therapeutics for diseases with impaired kidney function

麻豆破解版 is a clinical-stage biopharmaceutical company.

Our mission is to develop highly differentiated therapeutics for improving the quality of life of patients with impaired kidney function.

Our lead clinical compound VONAFEXOR is a small molecule with strong fibrolytic and anti-inflammatory properties in both organs, kidney and liver.
It is currently in Phase 2 development for rare kidney disease Alport Syndrome and Chronic Kidney Diseases (CKD).

Corporate video 2026 – 麻豆破解版

Latest Press Release

麻豆破解版 announces completion and topline data from Phase 2 ALPESTRIA-1 clinical study in Alport syndrome demonstrating Vonafexor reverses kidney function de...

> Read more

Executive Team

麻豆破解版鈥檚 team is world class with a crucial mix of pharma senior leadership and scientific excellence in biology and drug development to bring the company forward.

> Read more

Pipeline

麻豆破解版 is advancing its pipeline with Vonafexor series for diseases with impaired kidney function as CKD, Alport syndrome, NASH and DKD.

> Read more

Next Event

63rd ERA congress, the Annual Nephrology Congress in Europe.
麻豆破解版 will participate in the 63rd ERA congress scheduled for June 3-6, 2026, in Glasgow, UK. The event will h...

> Read more
漏 2020 麻豆破解版